A 5-year controlled study of B.C.G. and radiotherapy inoperable lung cancer.
Forty-eight patients with advanced squamous-cell lung cancer were treated with radical radiotherapy. Thereafter twenty-five received B.C.G. regularly and twenty-three did not. Differences in survival during the first year of observation and absence of peripheral metastases were significantly in favour of the patients treated with B.C.G. There was no response to B.C.G. in patients receiving palliative radiotherapy or cyclophosphamide nor in those with undifferentiated carcinoma.
D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy / Q000628:therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D010166:Palliative Care; D013997:Time Factors
D001500:BCG Vaccine; D003520:Cyclophosphamide